Tom Hallam, President and COO and Tom Meyer, VP, Business DevelopmentFacet determined that the existing data was already sufficient to support an NDA submission. They reframed the regulatory strategy, engaged with the FDA, and secured agreement to move forward. The result: savings of millions of dollars and two to three years of development time — for a single client, in a single engagement… and a new product to patients!
It wasn't luck. It's what they do. It is the Facet model in action. They take nothing as a given, are creative, and find the best path to FDA approval.
Better by Design: Purpose-Built for Emerging Biotech Companies
Emerging biotech companies, operating with limited capital and compressed timelines, must identify the most efficient path to approval. Aggressive regulatory strategy, clinical study design and evidence planning are key to achieving value-building milestones.
Facet was built with one need in mind: the emerging biotech company operating with limited resources and compressed timelines. They have one "shot on goal" and need it to be right 100% of the time.
Purpose-built for small biotech companies, Facet intentionally recruits senior-level professionals with deep, domain-specific expertise — scientists who have run these programs before, met with the FDA, and know how to build a compelling story. Facet’s clients get a team who can apply a breadth of experiences directly to their program.
Whether the goal is early proof-of-concept data for out-licensing to large pharma companies or the fastest path to full-scale commercialization, Facet’s experienced industry veterans tailor strategies in line with the clients’ business objectives. Facet’s focus is on maximizing ROI for every R&D spend.
“We leverage our knowledge of the science and deep experience with the FDA to help clients navigate regulatory, clinical and nonclinical hurdles with speed and efficiency,” says Tom Hallam, President and COO.
Facet provides guidance across the full drug development lifecycle — from initial IND through NDA approval, and across regulatory, clinical, statistical, and commercial domains. For Sponsors with deep in-house capability in any of these areas, the firm provides an independent second set of eyes. For Sponsors without these skillsets, Facet can fill in almost any knowledge gap - as an internal check on the work being done by CROs, a sounding board, or handling all the activities needed through FDA approval.
-
We leverage our knowledge of the science and deep experience with the FDA to help clients navigate regulatory, clinical and nonclinical hurdles with speed and efficiency.
Facet’s statistical team is particularly valued in this role. Many emerging biotechs rely on their CROs to provide analytical insight without any internal capability to validate it. Facet's statisticians close that gap.
Integrating commercial insight early in the process helps clients understand market dynamics and determine the drug’s value potential upfront. These decisions have cascading effects on the trial count and approval timelines, saving time and resources.
Challenging Industry Norms for Enhanced Outcomes
For decades, the biotech industry has assumed that companies must trade off between quality, speed and cost during candidate development.
Facet challenges this belief. In each engagement, it brings the right scientific expertise and planning to deliver high-quality outcomes while reducing timelines and controlling costs.
Emerging biotechs need expert advisors who understand their constraints, share their urgency, and bring the kind of creative, innovative thinking that can make a real difference to timeline and cost. They need partners who act like fiduciaries, like Facet.
Facet’s message is simple: a smarter path to FDA approval exists. It starts with asking the right questions and having the right partner to answer them.
Navigating Regulatory Complexity in Emerging Biotech Development
Regulatory strategy in life sciences has shifted from a compliance exercise to a defining factor in whether a therapy reaches patients at all. Executives overseeing development programs face a landscape where evolving FDA expectations, compressed funding cycles and heightened scrutiny around evidence generation intersect. Traditional development models, built for large pharmaceutical organizations with extensive resources, often fail to translate to emerging biotech environments where capital efficiency and speed carry equal weight to scientific rigor.
Uncertainty in regulatory pathways has become a central challenge. Agencies continue to refine guidance across biologics, personalized therapies and novel modalities, creating ambiguity in how evidence packages should be constructed. Early-stage companies, in particular, struggle to determine how much data is sufficient at each milestone. Overbuilding evidence can delay timelines and exhaust capital, while under-preparing risks rejection or costly rework. The consequence is a persistent tension between caution and progress that requires experienced judgment rather than procedural adherence.
Effective regulatory leadership begins with clarity around business intent. Development pathways differ significantly depending on whether a company aims to secure early proof of concept for partnership or carry a product through full approval and commercialization. Aligning regulatory decisions to that objective ensures that every study, interaction and submission contributes directly to the intended outcome rather than following a generalized pathway. This alignment reduces unnecessary work and avoids missteps that cascade into later stages of development.
Early-stage decision-making holds disproportionate influence over program success. Conversations with regulators, trial design choices and endpoint selection create downstream implications that can alter timelines by years. Programs that engage in disciplined planning at inception are better positioned to avoid redundant studies and reposition quickly when data evolves. The ability to interpret emerging results and adjust strategy without compromising regulatory acceptance has become a defining capability in modern development.
Scientific narrative also plays a critical role. Regulatory agencies ultimately evaluate whether a therapy is safe, effective and meaningful for patients. Translating complex data into a coherent argument that demonstrates these outcomes requires more than technical execution. It demands an understanding of how evidence is perceived, how risk is contextualized and how to present findings in a way that aligns with regulatory expectations. Companies that succeed in this area tend to focus not only on generating data but on ensuring that the data clearly supports a compelling case for approval.
Continuity across development stages further distinguishes effective programs. Fragmentation between regulatory, clinical and commercial planning often leads to misalignment, particularly when commercialization considerations are deferred. Early visibility into market positioning, patient populations and payer expectations informs better scientific and regulatory choices. Organizations that integrate these perspectives from the outset are more likely to pursue development paths that balance feasibility, value and long-term viability.
Facet Life Sciences exemplifies this integrated approach by focusing on emerging biotech companies and aligning regulatory strategy closely with business objectives. It brings an experienced team that guides clients through regulatory, clinical and manufacturing considerations while emphasizing efficient evidence generation. Its approach centers on identifying opportunities to streamline development, often enabling clients to avoid unnecessary studies and reduce both time and cost. The firm supports programs from early development through submission while maintaining continuity through data interpretation and strategic adjustments. By combining regulatory insight with scientific framing and commercial awareness, it positions itself as a strong partner for companies aiming to advance therapies efficiently without compromising quality.
...Read more
